# First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05875168/  
OnCo record `nct05875168` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of DS-3939a in advanced solid tumours, run by Daiichi Sankyo, now recruiting.

## Summary

First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05875168 by Daiichi Sankyo, with 590 participants planned, started 2023-08-18 and due to reach its primary completion in 2026-10-20. Interventions recorded: DS-3939a.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05875168
- Phase: 1/2
- Setting: Phase 1/2, Open-label, Multicenter, First-in-Human Study of DS-3939a in Subjects With Advanced Solid Tumors
- Sponsor: Daiichi Sankyo
- Enrolled: 590

## Sources

- ClinicalTrials.gov NCT05875168: https://clinicaltrials.gov/study/NCT05875168

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Daiichi Sankyo](https://onco.cc/companies/daiichi-sankyo/)

---
JSON: https://onco.cc/api/v1/entities/nct05875168.json